Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

385 Press Releases
DateTitleCompany
17 Nov 15 NICE Endorsed Tool Launched to Support Patients and Doctors in Shared Decision-Making. Boehringer Ingelheim,
Published by
Business Wire
16 Nov 15 Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab Boehringer Ingelheim,
Published by
PharmiWeb.com
16 Nov 15 Boehringer Ingelheim Presents New Praxbind® (idarucizumab) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran Boehringer Ingelheim,
Published by
PharmiWeb.com
16 Nov 15 Real-World Analysis of More Than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) in Routine Clinical Care Boehringer Ingelheim,
Published by
PharmiWeb.com
02 Nov 15 Boehringer Ingelheim Recognized on Science Magazine's 2015 Top Employer List Boehringer Ingelheim ,
Published by
PharmiWeb.com
02 Nov 15 Boehringer Ingelheim and BioMed X Extend Collaboration to Discover Novel Therapeutic Concepts for the Treatment of Psychiatric Diseases Boehringer Ingelheim ,
Published by
PharmiWeb.com
02 Nov 15 Boehringer Ingelheim Recognized on Science Magazine's 2015 Top Employer List Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
30 Oct 15 Boehringer Ingelheim Release CHEST: New Sub-Analyses Show Improvement In COPD Patient Outcomes With Spiolto Respimat Boehringer Ingelheim ,
Published by
PharmiWeb.com
30 Oct 15 Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab Boehringer Ingelheim,
Published by
PharmiWeb.com
28 Oct 15 Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab Boehringer Ingelheim,
Published by
Business Wire
28 Oct 15 New Results From a Patient Registry Reveal Insights About Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Oct 15 New Sub-Analyses Presented for STIOLTO RESPIMAT Across a Range of COPD Patient-Reported Outcomes Measures Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Oct 15 New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim ,
Published by
PharmiWeb.com
27 Oct 15 New Sub-Analyses Presented for STIOLTO RESPIMAT Across a Range of COPD Patient-Reported Outcomes Measures Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
22 Oct 15 New Results From a Patient Registry Reveal Insights About Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
19 Oct 15 FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
Business Wire
15 Oct 15 New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies Boehringer Ingelheim ,
Published by
PharmiWeb.com
08 Oct 15 Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study Boehringer Ingelheim,
Published by
PharmiWeb.com
28 Sep 15 New Head-to-Head STIOLTO RESPIMAT Data Presented at ERS Annual Congress Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
27 Sep 15 ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status Boehringer Ingelheim,
Published by
Business Wire
27 Sep 15 VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone Boehringer Ingelheim,
Published by
Business Wire
29 Sep 15 New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
01 Oct 15 CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Oct 15 VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Oct 15 COPD: New data support role of Spiolto® Respimat® as 1st-line maintenance therapy and show superiority over LABA/ICS Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Oct 15 New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Oct 15 ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Sep 15 COPD: New Data Support Role of Spiolto® Respimat® as 1st-line Maintenance Therapy and Show Superiority over LABA/ICS Boehringer Ingelheim,
Published by
Business Wire
08 Oct 15 Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study Boehringer Ingelheim,
Published by
Business Wire
08 Oct 15 Delayed IPF diagnosis negatively impacts patients by delaying treatment according to global survey of pulmonologists1 Boehringer Ingelheim,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.